Determining the optimal frequency of SARS-CoV-2 regular asymptomatic testing: A randomized feasibility trial in a home care setting

Author:

Butzmann JanaORCID,Hellriegel-Nehrkorn Annett,Dilas Milica,Pohl RobertORCID,Hellmich Martin,Apfelbacher Christian J.,Kaasch Achim J.ORCID

Abstract

Background The SARS-CoV-2 pandemic presented a challenge for caregiving relatives in the home care setting. Caregivers can transmit SARS-CoV-2 to their relatives who are often at high risk for a severe course of COVID-19. Regular testing of asymptomatic caregivers for SARS-CoV-2 may reduce the risk of transmission. The optimal method and frequency of regular asymptomatic testing is unknown. We conducted a prospective, randomised trial to assess the feasibility, recruitment and acceptance of different testing frequencies. This serves to inform a future definitive randomised controlled trial. Methods We carried out a parallel three-armed feasibility trial, enrolling adult participants who provided home-based care for a relative at least twice a week. Participants were randomly assigned using sealed envelopes to either conduct saliva-based antigen self-testing at a frequency of once a week (group I), twice a week (group II), or every two days (group III). The participants completed questionnaires on a weekly basis. Main outcome measures were feasibility of recruitment, adherence to self-tests and distress caused by self-testing. We further collected data on the use of mouth-nose mask. Results From 25 March to 7 May 2021 we assessed 27 participants and randomised 26 in the study: 8 participants in group I, 8 in group II and 10 in group III. All participants completed the study. In group I 48/48 (100.0%; 95% CI 92.6% to 100.0%), in group II 93/96 (96.9%; 95% CI 91.2% to 98.9%) and in group III 209/210 (99.5%; 95% CI 97.4% to 99.9%) self-tests were carried out at home. Participants did not perceive regular self-testing as burdensome in any of the study arms. We did not observe any infection with SARS-CoV-2. During the study, mask adherence decreased from 35% to 19% in all groups. Conclusion Conducting such a study was feasible. The participants tolerated regular self-testing well, which was reflected in a high level of test adherence. However, regular self-testing may have led to decreased protective behaviour. To demonstrate that regular asymptomatic testing reduces infection transmission, a future definitive trial should be performed at a time of a high prevalence of SARS-CoV-2 and be implemented as a multicentre study. Trial registration The trial is registered with the German Clinical Trials Register, DRKS00026234.

Funder

Bundesministerium für Bildung und Forschung

Publisher

Public Library of Science (PLoS)

Reference33 articles.

1. Robert Koch-Institut (RKI). Antworten auf häufig gestellte Fragen zur COVID-19-Pandemie: Was war die COVID-19-Pandemie? 18.09.2023 [cited 2024 March 24] https://www.rki.de/SharedDocs/FAQ/NCOV2019/FAQ-Liste-COVID-19-Pandemie.html

2. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes;J Li;J Med Virol,2021

3. Berufstätige Personen mit gleichzeitiger Erziehungs- und Pflegeverantwortung. [Employed persons caring simultaneously for children and care-dependent relatives—a scoping review];D. Bauernschmidt;Pflege,2020

4. Die verschiedenen Phasen der COVID-19-Pandemie in Deutschland: Eine deskriptive Analyse von Januar 2020 bis Februar 2021. [The different periods of COVID-19 in Germany: a descriptive analysis from January 2020 to February 2021];J Schilling;Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz,2021

5. Robert Koch-Institut. Epidemiologisches Bulletin 25/2021. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/25_21.pdf?__blob=publicationFile

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3